MAO-IN-M30 dihydrochloride

• CAT Number: I045767
• CAS Number: 64821-19-8
• Molecular Formula: C14H16Cl2N2O
• Molecular Weight: 299.20
• Purity: ≥95%
• Synonyms: 5-[[methyl(prop-2-ynyl)amino]methyl]quinolin-8-ol;dihydrochloride
• InChI: InChI=1S/C14H14N2O.2ClH/c1-3-9-16(2)10-11-6-7-13(17)14-12(11)5-4-8-15-14;;/h1,4-8,17H,9-10H2,2H3;2*1H
• InChIKey: XJNICPXVRPOSSO-UHFFFAOYSA-N
• SMILES: CN(CC#C)CC1=C2C=CC=NC2=C(C=C1)O.Cl.Cl

MAO-IN-M30 dihydrochloride is an orally active, brain-permeable, and brain selective irreversible MAO-A (IC50=37 nM) and MAO-B (IC50=57 nM) inhibitor. MAO-IN-M30 dihydrochloride is a potent iron chelator and radical scavenger. MAO-IN-M30 dihydrochloride has a neuroprotective effect against Dexamethasone-induced brain cell apoptosis. MAO-IN-M30 dihydrochloride also exhibits neurorestorative activity in post MPTP and lactacystin models of Parkinson’s disease[1][2][3]. MAO-IN-M30 (dihydrochloride) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
MAO-IN-M30 (0.25 nM; 72 hours) significantly increased cell viability to ~90% after exposure to Dexamethasone[3].
MAO-IN-M30 (0-10 μM; 24 hours) enhances PC12 cell survival[4].
MAO-IN-M30 treatment significantly decreases the occurrence of fragmented DNA compared to the dexamethasone-treated group in SH-SY5Y cells[3].
MAO-IN-M30 (0.5-2.5 mg/kg; p.o.; once daily for 14 consecutive days) possesses neuroprotective activities[6].

Reference

[1]. Gal S, et al. M30, a novel multifunctional neuroprotective drug with potent iron chelating and brain selective monoamine oxidase-ab inhibitory activity for Parkinson’s disease. J Neural Transm Suppl. 2006;(70):447-456.
 [Content Brief]

[2]. Zheng H, et al. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition. J Neurochem. 2005;95(1):68-78.
 [Content Brief]

[3]. Gal S, et al. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion. J Neurochem. 2005;95(1):79-88.
 [Content Brief]

[4]. Gal S, et al. Restoration of nigrostriatal dopamine neurons in post-MPTP treatment by the novel multifunctional brain-permeable iron chelator-monoamine oxidase inhibitor drug, M30. Neurotox Res. 2010;17(1):15-27.
 [Content Brief]